updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
Published 5 years ago • 149 plays • Length 2:54Download video MP4
Download video MP3
Similar videos
-
3:18
keynote-199: an update on pembrolizumab for mcrpc
-
2:47
dr. antonarakis on updated analysis of the keynote-199 trial in mcrpc
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
-
2:35
keynote 199 cohorts 4 & 5: enzalutamide and pembrolizumab for mcrpc
-
3:44
updates from the cheiron study: docetaxel plus enzalutamide for mcrpc
-
1:25
procaid: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mcrpc
-
2:38
keynote-365 cohort a: pembrolizumab plus olaparib in docetaxel-pretreated patients with mcrpc
-
1:20
dr. graff on results of the keynote-199 trial in mcrpc
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
2:06
saprocan: saracatinib and docetaxel for mcrpc
-
1:05
combining a dna vaccine with pembrolizumab for mcrpc
-
4:15
keynote-365: pembrolizumab combination therapy for mcrpc
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
1:24
dr. posadas on a phase ib study of abiraterone plus docetaxel for mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
4:54
background of the keynote-158 trial for pembrolizumab in advanced mesothelioma
-
0:55
post-progression therapies in patients with mcrpc progressing after docetaxel
-
28:36
role of chemotherapy, treatment sequencing in mcrpc and future directions
-
2:23
daniel petrylak, emso 2019 - phase iii keynote-321 study in prostate cancer